BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 225 filers reported holding BRIDGEBIO PHARMA INC in Q3 2023. The put-call ratio across all filers is 0.81 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,637,000 | -2.9% | 100,000 | +72.5% | 0.48% | -29.7% |
| Q3 2021 | $2,717,000 | -23.1% | 57,978 | 0.0% | 0.69% | -11.1% |
| Q2 2021 | $3,534,000 | -12.0% | 57,978 | -11.0% | 0.77% | -17.1% |
| Q1 2021 | $4,015,000 | -25.9% | 65,174 | -14.4% | 0.93% | -32.8% |
| Q4 2020 | $5,415,000 | +91.8% | 76,143 | +1.2% | 1.39% | +85.7% |
| Q3 2020 | $2,823,000 | +15.1% | 75,228 | +0.0% | 0.75% | +8.1% |
| Q2 2020 | $2,453,000 | +12.5% | 75,215 | 0.0% | 0.69% | -31.7% |
| Q1 2020 | $2,181,000 | – | 75,215 | – | 1.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $160,016,456 | 65.94% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $819,077,805 | 28.79% |
| Cormorant Asset Management, LP | 4,662,530 | $122,950,916 | 7.17% |
| Frazier Life Sciences Management, L.P. | 2,725,949 | $71,883,275 | 4.77% |
| Octagon Capital Advisors LP | 971,639 | $25,622,120 | 3.94% |
| M28 Capital Management LP | 121,200 | $3,196,044 | 3.66% |
| VIKING GLOBAL INVESTORS LP | 25,120,991 | $662,440,533 | 2.69% |
| BOONE CAPITAL MANAGEMENT LLC | 313,381 | $8,263,857 | 2.61% |
| Fernwood Investment Management, LLC | 235,620 | $6,213,299 | 2.23% |
| SOUTHPORT MANAGEMENT, L.L.C. | 15,000 | $395,550 | 2.15% |